Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to nine newly hired, non-executive employees on July 1, 2026.

Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to nine newly hired, non-executive employees on July 1, 2026. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), are non-qualified stock options for an aggregate 453,500 shares at a $26.01 exercise price.

The options have a 10-year term and vest 25% on the first anniversary of each employee’s start date, then in equal monthly installments over the following 36 months, under the 2022 Damora Therapeutics Inducement Plan and related award agreements.

Positive

• Inducement grants cover 453,500 options for newly hired employees
• 10-year option term with structured four-year vesting schedule
• Grants align with Nasdaq Listing Rule 5635(c)(4) requirements

Negative

• Potential dilution from 453,500 new stock option grants

Argus Jul 2 session

+10.67% close to close Open Argus

Details

News Market Reaction – DMRA

On Jul 2, the first trading day after this news, DMRA closed 10.67% above the previous close.

Data tracked by StockTitan Argus for the Jul 2 session.

Market Context

On Jul 2, the first trading day after this news, the stock closed 10.7% above the previous close. A ...

Analysis

On Jul 2, the first trading day after this news, the stock closed 10.7% above the previous close. A strong positive reaction aligns with prior favorable responses to significant corporate updates, while past routine inducement grants saw modest moves. With low short positioning, enthusiasm may hinge on confidence in retaining and motivating new hires.

Key Figures

New hires: 9 employees Option grant size: 453,500 shares Option exercise price: $26.01 per share +3 more

New hires

9 employees

Recipients of July 1, 2026 inducement equity grants

Option grant size

453,500 shares

Aggregate non-qualified stock options in inducement grants

Option exercise price

$26.01 per share

Exercise price for inducement stock options granted July 1, 2026

Option term

10 years

Duration of non-qualified stock options under inducement grants

Cliff vesting portion

25%

Portion of options vesting on first anniversary of start date

Remainder vesting period

36 months

Monthly vesting period after first-year cliff for remaining options

Historical Context

5 past events · Latest: Jun 01

5 events

1. Jun 01

   Inducement grants

   24h Move

   -0.1%

   Routine inducement stock option grants to six new non-executive employees.

2. May 12

   Earnings results

   24h Move

   +4.6%

   Q1 2026 results with cash runway into 2029 and pipeline milestones outlined.

3. May 01

   Inducement grants

   24h Move

   -1.2%

   Inducement stock options for two new hires under the 2022 Inducement Plan.

4. Mar 30

   Inducement & CEO grants

   24h Move

   -4.8%

   Equity awards to new CEO and hires, including options and RSUs under inducement rules.

5. Mar 23

   CEO appointment

   24h Move

   +27.1%

   Appointment of Jennifer Jarrett as CEO and addition of two directors to board.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, inducement plan

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"with a 10-year term and an exercise price of $26.01 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

inducement plan regulatory

"subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common stock with a 10-year term and an exercise price of $26.01 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a non-qualified stock option award agreement.

About Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.

Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement grants did Damora Therapeutics (NASDAQ: DMRA) announce on July 1, 2026?

Damora Therapeutics announced non-qualified stock option inducement grants covering 453,500 shares to nine newly hired, non-executive employees. According to Damora, these options were granted on July 1, 2026 as material inducements to employment and approved by the Board’s independent Compensation Committee.

How many Damora Therapeutics (DMRA) shares are covered by the new inducement stock options?

The inducement stock options cover an aggregate of 453,500 shares of Damora common stock. According to Damora, all options were granted to nine newly hired, non-executive employees as part of their compensation packages under the company’s 2022 Inducement Plan.

What is the exercise price and term of the new Damora Therapeutics (DMRA) inducement options?

The inducement options have a 10-year term and an exercise price of $26.01 per share. According to Damora, these non-qualified stock options were granted under the 2022 Damora Therapeutics Inducement Plan and related non-qualified stock option award agreements.

How do Damora Therapeutics (DMRA) inducement grants vest for the nine new employees?

The inducement options vest 25% on the first anniversary of each employee’s start date. According to Damora, the remaining 75% vests in equal monthly installments over the following 36 months, creating a four-year vesting schedule tied to ongoing employment.

Under which plan were the Damora Therapeutics (DMRA) inducement stock options granted?

The inducement stock options were granted under the 2022 Damora Therapeutics Inducement Plan. According to Damora, the awards are also governed by the terms and conditions of a non-qualified stock option award agreement for each participating employee.

How does Nasdaq Listing Rule 5635(c)(4) relate to Damora Therapeutics (DMRA) inducement grants?

Damora states that the inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Damora, the rule allows equity awards as material inducements to employment without prior shareholder approval, when approved by an independent compensation committee.